Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1% – What’s Next?

Posted by on Jul 11th, 2026

Oncolytics Biotech Inc. (NASDAQ:ONCY – Get Free Report) traded up 16.1% during trading on Thursday . The company traded as high as $0.97 and last traded at $0.92. 2,195,041 shares traded hands during trading, an increase of 116% from the average session volume of 1,016,877 shares. The stock had previously closed at $0.7923.

Wall Street Analyst Weigh In

ONCY has been the topic of several research analyst reports. Wall Street Zen downgraded shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings cut shares of Oncolytics Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Oncolytics Biotech in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Read Our Latest Stock Report on ONCY

Oncolytics Biotech Stock Down 3.6%

The company has a market capitalization of $105.90 million, a P/E ratio of -2.86 and a beta of 1.09. The business has a fifty day moving average price of $0.89 and a 200 day moving average price of $0.96.

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). As a group, equities analysts forecast that Oncolytics Biotech Inc. will post -0.25 earnings per share for the current year.

Institutional Trading of Oncolytics Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in ONCY. Renaissance Technologies LLC bought a new stake in shares of Oncolytics Biotech in the first quarter worth $608,000. PFG Investments LLC grew its position in Oncolytics Biotech by 131.0% in the first quarter. PFG Investments LLC now owns 52,900 shares of the company’s stock valued at $45,000 after purchasing an additional 30,000 shares in the last quarter. Virtu Financial LLC acquired a new stake in Oncolytics Biotech in the 4th quarter valued at $68,000. Connective Capital Management LLC acquired a new stake in Oncolytics Biotech in the 4th quarter valued at $131,000. Finally, XTX Topco Ltd bought a new stake in Oncolytics Biotech during the 4th quarter worth about $69,000. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

(Get Free Report)

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.

Featured Articles

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.